The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlation between strength of T-cell response against HPV16 and survival after vaccination with HPV16 long peptides in combination with chemotherapy for late-stage cervical cancer.
 
Cornelis Joseph Melief
Employment - ISA Pharmaceuticals
Stock and Other Ownership Interests - ISA Pharmaceuticals
Honoraria - GlaxoSmithKline; Immatics
Consulting or Advisory Role - GlaxoSmithKline (Inst); Immatics (Inst)
Patents, Royalties, Other Intellectual Property - ISA Pharmaceuticals
Expert Testimony - Merck
 
Winald R. Gerritsen
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; CureVac; Janssen-Cilag; Merck Sharp & Dohme; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen-Cilag (Inst)
 
Marij Welters
No Relationships to Disclose
 
Ignace Vergote
Consulting or Advisory Role - Amgen (Inst); Array Biopharma (Inst); AstraZeneca (Inst); Biogen (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Endocyte (Inst); Fresenius (Inst); GE Healthcare (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hampton Medical Conferences (Inst); Intuitive Surgical (Inst); Janssen-Cilag (Inst); Kendle (Inst); Lilly (Inst); MedImmune (Inst); Menarini (Inst); Merck Sharp & Dohme (Inst); Morphotek (Inst); Nektar (Inst); Novo Nordisk (Inst); Oasmia Pharmaceutical AB (Inst); PharmaMar (Inst); Phillips Gilmore Oncology (Inst); Quintiles (Inst); Roche (Inst); Sanofi (Inst); Schering-Plough (Inst); Sigma-Tau (Inst); Telik (Inst); TRM Oncology (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); Exelixis (Inst); Fresenius Biotech (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Morphotek (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Proacta (Inst); Quintiles (Inst); Roche (Inst); Sandoz (Inst); Sanofi (Inst); Schering-Plough (Inst); Vifor Pharma (Inst); Wyeth (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GCI Health; Oasmia Pharmaceutical AB; PharmaMar; Roche
 
Judith R. Kroep
No Relationships to Disclose
 
Gemma Kenter
No Relationships to Disclose
 
P. B. Ottevanger
No Relationships to Disclose
 
Wiebren Age Tjalma
No Relationships to Disclose
 
Hannelore Denys
No Relationships to Disclose
 
Hans Nijman
No Relationships to Disclose
 
Mariette IE van Poelgeest
No Relationships to Disclose
 
An K.L Reyners
No Relationships to Disclose
 
Thierry J. Velu
No Relationships to Disclose
 
Brent A. Blumenstein
No Relationships to Disclose
 
Frederic Goffin
No Relationships to Disclose
 
Roy Iqbal Lalisang
No Relationships to Disclose
 
Richard B. Stead
No Relationships to Disclose
 
Sjoerd van der Burg
Consulting or Advisory Role - ISA Pharmaceuticals
Research Funding - ISA Pharmaceuticals
Patents, Royalties, Other Intellectual Property - ISA Pharmaceuticals